Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Key Highlights
- ➤PLN-101095 gets two presentations at the 2026 SITC annual meeting
- ➤FORTIFY Phase 1b enrolls NSCLC, high-TMB tumors, and clear cell renal cell carcinoma patients
- ➤PLN-101095 is tested with pembrolizumab in ICI-refractory advanced solid tumors
- ➤Phase 1b dosing starts with PLN-101095 1,000 mg twice daily for 14 days
Expert Statements
Nika Rajabian, Postdoctoral Fellow, National Cancer Institute
“Selective targeting of integrins αvβ8 and αvβ1 improves anti-tumor responses mediated by immune checkpoint inhibition”
Martin L. Decaris, Vice President, Translational Sciences, Pliant Therapeutics
“Plasma biomarkers of immune activation predict sensitization to immune checkpoint inhibition (ICI) in patients with advanced solid tumors receiving dual αvβ8/αvβ1 integrin inhibitor PLN-101095”
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41(st) Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona.
Title: Selective targeting of integrins αvβ8 and αvβ1 improves anti-tumor responses mediated by immune checkpoint inhibition
Get started
Create a free account to read the full story.